EyePoint Secures Two US Patents for DEXYCU

April 13, 2018: By Jon Swedien

EyePoint Pharmaceuticals

The US Patent and Trademark Office (USPTO) issued EyePoint Pharmaceuticals a notice of allowance for two patents covering DEXYCU, the Watertown, Massachusetts-based company (formerly pSivida) announced April 12.

DEXYCU (dexamethasone intraocular suspension) is FDA-approved for the treatment of postoperative inflammation associated with cataract surgery.

The first patent includes claims relating to a method of treating inflammation of an eye following cataract surgery by delivering extremely small (4-6µL) amounts of dexamethasone in triethyl acetyl citrate, EyePoint said. Once issued, the patent will expire in 2034, the company said.

The second patent includes claims relating to loading and delivering a small dose volume from an injection syringe. Once issued, it will expire in 2032.

After issuing a notice of allowance, the USPTO requires applicants to pay fees before it issues patents.

DEXYCU delivers a biodegradable extended-release formulation of dexamethasone into the posterior chamber of the eye via a single injection at the end of surgery, eliminating a patient’s need to take medicated eye drops several times a day for several weeks on a titrated schedule, EyePoint said.

DEXYCU employs the firm’s Verisome technology to dispense a biodegradable extended-release formulation of dexamethasone into the anterior chamber of the eye, EyePoint said.

EyePoint was formed after pSivida Corp acquired privately held Icon Bioscience of Newark, California, in March and rebranded.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

Ivantis Gains US FDA Approval for Hydrus Microstent

US FDA Approves Sun Pharma’s CEQUA for Dry Eye

Regeneron Receives US FDA Approval for 12-Week Eylea Dosing

STAAR, Japan’s Shinjuku LASIK Clinic Sign Multiyear Agreement

Alcon Launches Finesse Sharkskin ILM Forceps

Imprimis’ Q2-2018 Revenues Increase 51 Percent to $10.4 Million

Bausch Health Revenues in Q2-2018 Drop 5 Percent

TearLab’s Q2-2018 Revenues Drop 8.5 Percent to $6.4 Million

DeepMind AI System Accurately Detects Eye Disease in OCT Scans at Moorfields

Study by MIT, Mass Eye and Ear Suggests Glaucoma is Autoimmune Disease

Study Indicates Insulin May Restore Vision in Glaucoma

CHOP Researchers Define Six ROP Indicators

Nicox Initiates Phase II Study of NCX 470 in Open-Angle Glaucoma, Ocular Hypertension

Eyenovia’s Microdose Latanoprost Delivers Drug with Precision, Lowers IOP in Proof-of-Concept Study

Rayner to Launch Sulcoflex Trifocal Toric IOL in September

CMS Allows Medicare Advantage Plans to Apply Step Therapy to Retinal Injections

Glaukos Reports Drug Collaboration with D. Western, Q2-2018 Net Sales Increase of 5 Percent

Allergan Will Co-develop Editas’ CRISPR Genome Editing Candidate for LCA10

Spark Reports Q2-2018 Net Sales of $4.3 Million for Luxturna

Aerie’s Rhopressa Posts $2.4 Million in Net Revenues in Q2-2018

Coming soon

2018 Ophthalmic Laser Report: A Global Market Analysis for 2017 to 2023 (Photocoagulation, Photodisruption, and SLT